• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

移植肾活检中组织内调节性 T 细胞保留 foxp3 去甲基化,是保护肾脏移植物预后的生物标志物。

Intragraft regulatory T cells in protocol biopsies retain foxp3 demethylation and are protective biomarkers for kidney graft outcome.

机构信息

Department of Nephrology Laboratory of Experimental Nephrology, Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.

出版信息

Am J Transplant. 2011 Oct;11(10):2162-72. doi: 10.1111/j.1600-6143.2011.03633.x. Epub 2011 Jul 12.

DOI:10.1111/j.1600-6143.2011.03633.x
PMID:21749644
Abstract

Presence of subclinical rejection (SCR) with IF/TA in protocol biopsies of renal allografts has been shown to be an independent predictor factor of graft loss. Also, intragraft Foxp3+ T(reg) cells in patients with SCR has been suggested to differentiate harmful from potentially protective infiltrates. Nonetheless, whether presence of Foxp3 T(reg) cells in patients with SCR and IF/TA may potentially protect from a deleterious graft outcome has not yet been evaluated. This is a case-control study in which 37 patients with the diagnosis of SCR and 68 control patients with no cellular infiltrates at 6-month protocol biopsies matched for age and time of transplantation were evaluated. We first confirmed that numbers of intragraft Foxp3-expressing T cells in patients with SCR positively correlates with Foxp3 demethylation at the T(reg) -specific demethylation region. Patients with SCR without Foxp3+ T(reg) cells within graft infiltrates showed significantly worse 5-year graft function evolution than patients with SCR and Foxp3+ T(reg) cells and those without SCR. When presence of SCR and IF/TA were assessed together, presence of Foxp3+ T(reg) could discriminate a subgroup of patients showing the same graft outcome as patients with a normal biopsy. Thus, presence of Foxp3+ T(reg) cells in patients with SCR even with IF/TA is associated with a favorable long-term allograft outcome.

摘要

移植肾活检中存在亚临床排斥反应(SCR)伴免疫荧光/组织化学染色阳性(IF/TA)已被证实是移植物丢失的独立预测因素。此外,SCR 患者移植组织内 Foxp3+T 调节细胞(Treg)已被认为可区分有害和潜在保护性浸润。然而,SCR 伴 IF/TA 患者的 Foxp3+Treg 细胞是否可能对有害移植物结局有保护作用尚未得到评估。本研究为病例对照研究,纳入 37 例 SCR 患者和 68 例年龄和移植时间匹配的 6 个月时移植肾活检未见细胞浸润的对照组患者。首先,我们证实 SCR 患者移植组织内 Foxp3 表达 T 细胞数量与 Treg 特异性去甲基化区 Foxp3 去甲基化呈正相关。与 SCR 伴 Foxp3+Treg 细胞和无 SCR 的患者相比,SCR 患者移植组织内无 Foxp3+Treg 细胞的患者 5 年移植物功能演变明显较差。当同时评估 SCR 和 IF/TA 时,Foxp3+Treg 的存在可区分一组与活检正常患者具有相同移植物结局的患者。因此,SCR 患者即使存在 IF/TA,Foxp3+Treg 细胞的存在也与长期移植物预后良好相关。

相似文献

1
Intragraft regulatory T cells in protocol biopsies retain foxp3 demethylation and are protective biomarkers for kidney graft outcome.移植肾活检中组织内调节性 T 细胞保留 foxp3 去甲基化,是保护肾脏移植物预后的生物标志物。
Am J Transplant. 2011 Oct;11(10):2162-72. doi: 10.1111/j.1600-6143.2011.03633.x. Epub 2011 Jul 12.
2
Presence of FoxP3+ regulatory T Cells predicts outcome of subclinical rejection of renal allografts.FoxP3+调节性T细胞的存在可预测肾移植亚临床排斥反应的结果。
J Am Soc Nephrol. 2008 Oct;19(10):2020-6. doi: 10.1681/ASN.2007111174. Epub 2008 May 21.
3
Preferential accumulation of T helper cells but not cytotoxic T cells characterizes benign subclinical rejection of human liver allografts.人肝移植良性亚临床排斥反应的特征是辅助性T细胞而非细胞毒性T细胞的优先积聚。
Liver Transpl. 2016 Jul;22(7):943-55. doi: 10.1002/lt.24427.
4
Reduction of Foxp3-expressing regulatory T cell infiltrates during the progression of renal allograft rejection in a mouse model.在小鼠模型中,肾移植排斥反应进展过程中表达Foxp3的调节性T细胞浸润减少。
Transpl Immunol. 2008 May;19(2):93-102. doi: 10.1016/j.trim.2008.03.004. Epub 2008 Apr 28.
5
Achieving donor-specific hyporesponsiveness is associated with FOXP3+ regulatory T cell recruitment in human renal allograft infiltrates.实现供体特异性低反应性与人类肾移植浸润物中FOXP3 +调节性T细胞的募集有关。
J Immunol. 2007 Oct 1;179(7):4901-9. doi: 10.4049/jimmunol.179.7.4901.
6
Expression patterns of regulatory T-cell markers in accepted and rejected nonhuman primate kidney allografts.已接受和被排斥的非人灵长类动物肾移植中调节性T细胞标志物的表达模式。
Am J Transplant. 2007 Oct;7(10):2236-46. doi: 10.1111/j.1600-6143.2007.01917.x.
7
Regulatory T cells in kidney allograft infiltrates correlate with initial inflammation and graft function.移植肾浸润调节性 T 细胞与初始炎症和移植物功能相关。
Transplantation. 2010 Jan 27;89(2):194-9. doi: 10.1097/TP.0b013e3181c3ca11.
8
Ex vivo-expanded natural CD4+CD25+ regulatory T cells synergize with host T-cell depletion to promote long-term survival of allografts.体外扩增的天然CD4+CD25+调节性T细胞与宿主T细胞耗竭协同作用,以促进同种异体移植物的长期存活。
Am J Transplant. 2008 Feb;8(2):298-306. doi: 10.1111/j.1600-6143.2007.02088.x. Epub 2008 Jan 7.
9
Clinical significance of the ratio between FOXP3 positive regulatory T cell and interleukin-17 secreting cell in renal allograft biopsies with acute T-cell-mediated rejection.移植肾活检中 FOXP3 阳性调节性 T 细胞与白介素-17 分泌细胞比值对急性 T 细胞介导排斥反应的临床意义。
Immunology. 2012 Jul;136(3):344-51. doi: 10.1111/j.1365-2567.2012.03588.x.
10
Analysis of FOXP3 gene and protein expressions in renal allograft biopsies and their association with graft outcomes.分析肾移植活检组织中 FOXP3 基因和蛋白的表达及其与移植物结局的关系。
Ren Fail. 2013;35(4):521-30. doi: 10.3109/0886022X.2013.766568. Epub 2013 Feb 25.

引用本文的文献

1
Chronic Graft-versus-host Disease: Immune Insights, Therapeutic Advances, and Parallels for Solid Organ Transplantation.慢性移植物抗宿主病:免疫见解、治疗进展及实体器官移植的相似之处
Transplantation. 2025 Jun 1;109(6):955-966. doi: 10.1097/TP.0000000000005298. Epub 2024 Dec 17.
2
Intragraft regulatory T cells in the modern era: what can high-dimensional methods tell us about pathways to allograft acceptance?现代移植器官内调节性 T 细胞:高维方法能告诉我们哪些途径可以实现同种异体移植物的接受?
Front Immunol. 2023 Nov 23;14:1291649. doi: 10.3389/fimmu.2023.1291649. eCollection 2023.
3
CD4CD25 T regulatory cells in renal transplantation.
肾移植中的 CD4CD25T 调节性细胞。
Front Immunol. 2022 Nov 8;13:1017683. doi: 10.3389/fimmu.2022.1017683. eCollection 2022.
4
Therapeutic Opportunities for Immunoreceptor-Engineered T Cell Therapy for Modulation of Alloimmunity.免疫受体工程化 T 细胞治疗在调节同种异体免疫中的治疗机会。
J Immunol. 2022 Nov 15;209(10):1811-1816. doi: 10.4049/jimmunol.2200542.
5
Burnstock oration - purinergic signalling in kidney transplantation.嘌呤能信号在肾移植中的作用
Purinergic Signal. 2022 Dec;18(4):387-393. doi: 10.1007/s11302-022-09865-3. Epub 2022 Apr 26.
6
Epigenetic Regulation in Kidney Transplantation.肾移植中的表观遗传调控。
Front Immunol. 2022 Apr 8;13:861498. doi: 10.3389/fimmu.2022.861498. eCollection 2022.
7
The applications of DNA methylation as a biomarker in kidney transplantation: a systematic review.DNA 甲基化作为肾移植生物标志物的应用:系统评价。
Clin Epigenetics. 2022 Feb 7;14(1):20. doi: 10.1186/s13148-022-01241-7.
8
Tackling Chronic Kidney Transplant Rejection: Challenges and Promises.解决慢性肾移植排斥反应:挑战与希望。
Front Immunol. 2021 May 20;12:661643. doi: 10.3389/fimmu.2021.661643. eCollection 2021.
9
Evaluation of Thymic Output and Regulatory T Cells in Kidney Transplant Recipients with Chronic Antibody-Mediated Rejection.评估慢性抗体介导排斥反应的肾移植受者的胸腺输出和调节性 T 细胞。
Biomed Res Int. 2021 Feb 9;2021:6627909. doi: 10.1155/2021/6627909. eCollection 2021.
10
Unveiling the Role of DNA Methylation in Kidney Transplantation: Novel Perspectives toward Biomarker Identification.揭示 DNA 甲基化在肾移植中的作用:生物标志物鉴定的新视角。
Biomed Res Int. 2019 Jan 15;2019:1602539. doi: 10.1155/2019/1602539. eCollection 2019.